Cat. No. 1284
Chemical Name: 6-(Benzylamino)-2-(2-hydroxyethylam
Biological ActivityCyclin-dependent kinase inhibitor that competes for the ATP binding site of the kinase. Selectively inhibits cdc2/cyclin B (IC50 = 7 μM), cdk2/cyclin A (IC50 = 7 μM), cdk2/cyclin E (IC50 = 7 μM), cdk/p35 kinase (IC50 = 3 μM) and ERK1/MAP kinase (IC50 = 25 μM). Arrests human fibroblasts in the G1 phase.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Alessi et al (1998) The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp.Cell.Res. 245 8. PMID: 9828096.
Abraham et al (1995) Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol.Cell 83 105. PMID: 7549905.
Vesely et al (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur.J.Biochem. 224 771. PMID: 7925396.
If you know of a relevant reference for Olomoucine please let us know.
Citations are publications that use Tocris products. Selected citations for Olomoucine include:
Cannon et al (2009) Association of luteinizing hormone receptor gene expression with cell cycle progression in granulosa cells. Am J Physiol Endocrinol Metab 296 E1392. PMID: 19293332.
Do you know of a great paper that uses Olomoucine from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Olomoucine, supplier, Cyclin-dependent, protein, kinases, inhibitors, inhibits, Cdks, Tocris Bioscience, Cyclin-Dependent Protein Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomesSTK16-IN-1
Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits P13Kδ, P13Kγ and mTOR kinases.AZ PFKFB3 26
Potent and selective PFKFB3 inhibitorNCL 00017509
Potent and reversible NIMA related kinase 2 (Nek2) inhibitorXMD 8-87
Potent Ack1/TNK2 inhibitorSKI 178
Non-lipid sphingosine kinase 1 (SphK1) inhibitorML 315 hydrochloride
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitor
June 14 - 17, 2017
Boston, MA, USA